Noteworthy Work
K&L Gates Advises Anavex Life Sciences Corp. on US$150 Million Offering
Global law firm K&L Gates LLP has advised Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company pioneering innovative therapies for central nervous system (CNS) disorders, in a US$150 million at-the-market (ATM) public offering of common stock. TD Securities (USA) LLC acted as placement agent for the transaction.
Anavex is focused on developing treatments for a range of neurological and neurodevelopmental conditions, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other rare and degenerative CNS disorders. The offering supports the company’s continued advancement of its clinical pipeline and strategic growth initiatives.
The K&L Gates team advising on the transaction included Miami partners Clayton Parker and Erin Fogarty with support from Miami associates David McDonald and Arielle Flamenbaum.
“We are proud to support Anavex in this important financing, which will help accelerate the development of therapies targeting some of the most challenging neurological conditions,” said Parker. “This transaction reflects the growing investor confidence in innovative biotech companies addressing unmet medical needs.”
K&L Gates’ Corporate practice is one of the most substantial in the legal industry, with hundreds of lawyers in offices on five continents, providing clients with practical legal solutions in the structuring, financing, and completion of domestic, international, and cross-border transactions.
K&L Gates is a fully integrated global law firm with lawyers located across five continents. The firm represents leading multinational corporations, growth and middle-market companies, capital markets participants and entrepreneurs in every major industry group as well as public sector entities, educational institutions, philanthropic organizations and individuals.
